All first-tier NBS for Krabbe disease is based on measurement of the galactocerebrosidase (GALC) enzymatic activity in DBS using MS/MS [1,36] or fluorimetry with a 96-well plate reader. This evidence concerns the gene GALC and Krabbe disease.